AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04040686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of 99mTc-NM-02
Description: Patient will be injected with microdose (\<100ug) of 99mTc-NM-02 radiotracer
Study NCT04012528 — intervention group
Intervention type: OTHER
Intervention: ERAS program
Description: ERAS program
Study NCT01625468 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational print materials and a coaching call
Description: Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
Study NCT04237363 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Underwater treadmill training and supplemental overground walk training
Study NCT01066572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril
Description: 5-10 mg Lisinopril per day for seven days, depending on blood pressure.
Study NCT01066572 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo; identical tablets to Lisinopril.
Study NCT03279042 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flapless corticotomy surgical intervention will be conducted
Description: Piezocision will be used to perform the procedure
Study NCT03279042 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional corticotomy
Description: Here the surgery involves elevation of flaps and then conducting the surgical intervention using piezo-surgery cutting saws.
Study NCT01950962 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sampling of blood
Study NCT03087058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patiromer
Description: 4.2 g/day, 8.4 g/day and 16.8 g/day
Study NCT03087058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patiromer
Description: 2 g/day, 4 g/day and 8 g/day
Study NCT03087058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patiromer
Description: 1 g/day, 2 g/day and 4 g/day
Study NCT01376219 — intervention group
Intervention type: OTHER
Intervention: asthma control test
Description: results of asthma control testing collected
Study NCT01420536 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Occlusal scheme
Description: Before enrollment, all participants will receive conventional complete dentures adjusted according to the bilateral balanced occlusion concept.~Following randomization, canine guidance will be achieved by adding composite resin (Restorative Z100, 3M Brazil, Sumaré, SP, Brazil) on the lingual surface of the maxillary canines. A sham comparator will also employ the addition of composite, but without changing eccentric contacts.
Study NCT01420536 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Occlusal scheme
Description: Before enrollment, all participants will receive conventional complete dentures adjusted according to the bilateral balanced occlusion concept.~Following randomization, canine guidance will be achieved by adding composite resin (Restorative Z100, 3M Brazil, Sumaré, SP, Brazil) on the lingual surface of the maxillary canines. A sham comparator will also employ the addition of composite, but without changing eccentric contacts.
Study NCT00624988 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vibration Therapy
Description: Treatment will consist of 10 sessions of 60 seconds each with one minute intervals in between at 50 Hz frequency three times per week for three months.
Study NCT02911454 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant formula
Study NCT04352348 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood samples
Description: All arms:~1 blood sample at inclusion (T0)~COVID-19 positive, severe only:~1 blood sample at D3, at D7, in case of transfer to intensive care unit or in case of aggravation of symptoms, eventually, at discharge from hospital if the last blood sample was more than 3 days old, in case of post-COVID-19 follow-up visit scheduled in standard care at 3 to 6 months after hospitalization and in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization.~Follow-up after COVID-19 hospitalization only:~1 blood sample in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization
Study NCT04352348 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: feces samples (COVI-BIOME ancillary study)
Description: All arms:~1 feces sample at inclusion (T0)~COVID-19 positive, severe only:~1 feces sample at D3, at D7, in case of transfer to intensive care unit or in case of aggravation of symptoms and, eventually, at discharge from hospital
Study NCT04352348 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: sweat samples (COVIDOG ancillary study)
Description: All arms:~2 sweat samples at inclusion (T0)
Study NCT04352348 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: saliva samples
Description: All arms:~1 saliva sample at inclusion (T0)~COVID-19 positive, severe only:~1 saliva sample at D7, at discharge from hospital, in case of post-COVID-19 follow-up visit scheduled in standard care at 3 to 6 months after hospitalization and in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization.~Follow-up after COVID-19 hospitalization only:~1 blood sample in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization
Study NCT04352348 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 6 minutes walk test
Description: COVID-19 positive, severe only:~6 minutes walk test in case of post-COVID-19 follow-up visit scheduled in standard care at 3 to 6 months after hospitalization and in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization.~Follow-up after COVID-19 hospitalization only:~6 minutes walk test at inclusion (T0) and in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization.
Study NCT04352348 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Phone call
Description: All arms except COVID-19 negative:~1 phone call 3 months after COVID-19 infection.~All arms except COVID-19 negative:~1 phone call 6 months after COVID-19 infection.~All arms except COVID-19 negative:~1 phone call 12 months after COVID-19 infection.
Study NCT04352348 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Urine samples
Description: All arms:~1 urine sample at inclusion (T0)~COVID-19 positive, severe only:~1 urine sample at D3, at D7, at discharge from hospital, in case of post-COVID-19 follow-up visit scheduled in standard care at 3 to 6 months after hospitalization and in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization.~Follow-up after COVID-19 hospitalization only:~1 urine sample in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization
Study NCT02941640 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: E group
Description: The securing the base of appendix by endoloop.
Study NCT02941640 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: S group
Description: The securing the base of appendix by Stapler.
Study NCT02941640 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: H group
Description: The securing the base of appendix by Hem-o-lok clip.
Study NCT02941640 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DS group
Description: The securing the base of appendix by DS clip.
Study NCT02941640 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoloop
Study NCT02941640 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stapler
Study NCT02941640 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hem-o-lok clip
Study NCT02941640 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DS clip
Study NCT01738100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Study NCT01738100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Study NCT01738100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Study NCT01738100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulfate
Study NCT01738100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Study NCT01738100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Study NCT00988702 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dan Tian Breathing
Description: Dan Tian Breathing for one month
Study NCT00988702 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive muscle training
Description: Progressive muscle training for one month
Study NCT01628536 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Black cohosh
Description: Remifemin 20 mg tablet orally twice per day x 4 weeks
Study NCT02605200 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychologist Support
Description: Participants will complete several psychological questionnaires that are intended to cover a broad spectrum of physical, mental, and emotional aspects of the health of participants; the Behavior Assessment System for Children (BASC) ,the Children Depression Inventory (CDI 2), the Pediatric Quality of Life Inventory Transplant Module (PedsQL), and the Wechsler Abbreviated Scale of Intelligence II (WASI-II). Data gathered from this testing will be used to guide the provision of psychological care to address psychosocial challenges inherent to the care of children with transplant related diabetes.
Study NCT02605200 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pediatric Certified Diabetes Educators (CDEs) Support
Description: Pediatric Certified Diabetes Educators (CDEs) are specially trained to teach diabetes self-management to children and their families. Participants who are diagnosed with diabetes will receive individualized support from a CDE in conjunction with their routine transplant care.
Study NCT03875001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1358894
Description: tablet
Study NCT03875001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet
Study NCT01449253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: 20 mg initially and then increased to 20 mg TDS if there is no fall in BP
Study NCT01449253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bosentan
Description: Bosentan 62.5 mg BD initially for 1 month and then increased to 125 mg BD
Study NCT00505635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 250 mg/m\^2 By Mouth Every 4 Hours x 3 Doses On Day 1
Study NCT00505635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velban
Description: 1.5 mg/m\^2 By Vein Over 15-30 Minutes On Days 1-4
Study NCT00505635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 20 mg/m\^2 By Vein Over 45-120 Minutes On Days 1-4
Study NCT00505635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: 9 MIU/m\^2 By Vein Over 24 Hours x 4 Doses On Days 1-4
Study NCT00505635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intron-A
Description: 5 mu/m\^2 Subcutaneously (Under the skin) Daily On Days 1-5
Study NCT00505635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 400 mg By Mouth Daily
Study NCT01340690 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ω-3 fatty acids suspension
Description: 2 bags of Esprico(R) suspension given orally once daily in the morning for 84 days
Study NCT01340690 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo suspension
Description: suspension to mimic verum Esprico (R) suspension. 2 bags of Esprico(R) placebo suspension given orally once daily in the morning for 84 days
Study NCT04606758 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCNL under fluoroscopic control
Description: Patients receive standard of care treatment for their urolithiasis using standard PCNL under fluoroscopic guidance
Study NCT04606758 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCNL under ultrasound control
Description: Patients receive standard of care treatment for their urolithiasis using standard PCNL under US guidance
Study NCT02523352 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-Invasive Ventilation
Description: Progressive increase in airway pressure to open lungs atelectatic regions.
Study NCT02523352 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophageal catheter positioning
Description: The esophageal tube (8 French diameter catheter) will be positioned in the larger nostril previous topical anesthesia
Study NCT03074500 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: Kinesio tape will be applied by using space correction and fascia correction technique on forearm of the patients for the treatment of lateral epicondylitis
Study NCT03074500 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham taping
Description: Sham taping will be performed without using any technique
Study NCT03074500 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Stretching exercises of wrist 30 seconds to one minute, twice a day and strengthening exercises will performed be 10 repetitions in 2 or 3 series. .
Study NCT03074500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Stretching exercises of wrist 30 seconds to one minute, twice a day and strengthening exercises will performed be 10 repetitions in 2 or 3 series. .
Study NCT03074500 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercise
Description: Stretching exercises of wrist 30 seconds to one minute, twice a day and strengthening exercises will performed be 10 repetitions in 2 or 3 series. .
Study NCT04433104 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Mesenchymal Stem Cells transplantation
Description: Patients assigned to UC-MSC administration groups will receive two administrations at a dose of 1 million cells/kg patient body weight via the IV route with a 3-month intervening interval
Study NCT04433104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: drug therapy according to Vietnamese MOHS procedure
Description: Salbutamol, Terbutaline
Study NCT04433104 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: drug therapy according to Vietnamese MOHS procedure
Description: Salbutamol, Terbutaline
Study NCT02206347 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: attention focus
Study NCT02313051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: mTOR inhibitor
Study NCT02313051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin
Study NCT02313051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Study NCT02313051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Study NCT02313051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Study NCT02302274 — intervention group
Intervention type: DRUG
Intervention: flecainide iv
Description: infusion over 10 min
Study NCT03760445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 20mg or 1000 mg or other strengths as locally available given intravenously
Study NCT03567681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended release oxcarbazepine vs Immediate release oxcarbazepine
Description: Extended release oxcarbazepine vs Immediate release oxcarbazepine
Study NCT03805594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium Lu 177-PSMA-617
Description: Given IV
Study NCT03805594 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT01059331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: 150 mg x 2 daily for 2 days
Study NCT01059331 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: 1 tablet x 2 daily, for 2 days
Study NCT04333004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Combined With Chemotherapy
Description: Pembrolizumab and chemotherapy are carried out at the same time for every 3 weeks
Study NCT01334086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Oral aprepitant will be given to the participant on Days 1-5 of standard induction treatment. A dose of 125 mg will be given on Day 1 and 80 mg will be given on Days 2-5.
Study NCT04331626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Injectable Product
Description: Low dose chemotherapy drug combined with pd-1 antibody, Gemcitabine should be administered at 50% of the recommended dose, i.e. 500mg/m2, for 30 minutes by intravenous drip. Day 1 and day 8 administration.
Study NCT02783170 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Tetanus, Diphtheria, and Pertussis Vaccine
Study NCT02783170 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 2016-2017 Quadrivalent Inactivated Influenza Vaccine
Study NCT02783170 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 2017-2018 Quadrivalent Inactivated Influenza Vaccine
Study NCT01797393 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Air insufflation
Description: Air is inflated into the bowel to help searching the cavity while advancing the colonoscope until reaching the cecum.
Study NCT01797393 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water injection
Description: Water was injected through the working channel instead of air to follow the intestinal cavity until reaching the caecum .
Study NCT01797393 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention:  Air assisted water injection.
Description: Cut off air inflating before examination. Water was injected through the working channel to follow the intestinal cavity until reaching the splenic flexure, small amount of air inflating could be given to help searching the cavity until reaching the cecum.
Study NCT02344329 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Topical wound dressing
Description: Topical Wound Dressing
Study NCT02344329 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Amnion Allograft
Description: Change dressing every two to three weeks and TCC-EZ is changed weekly for 12 or until healed.
Study NCT02344329 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual wound care
Description: assessment, wound cleansing, debridement, moist wound environment, and off-loading
Study NCT02344329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: usual wound care
Description: assessment, wound cleansing, debridement, moist wound environment, and off-loading
Study NCT02178904 — intervention group
Intervention type: PROCEDURE
Intervention: CT and stress test
Description: Coronary computed tomographic angiography (CCTA) plus computed tomography stress myocardial perfusion imaging (CTP)
Study NCT01198002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2127399
Description: Administered Subcutaneously (SC)
Study NCT03760445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anthracycline
Description: 20mg or other strength as locally available given intravenously
Study NCT01198002 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LY2127399
Description: Administered Subcutaneously (SC)
Study NCT01198002 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Q2W
Description: Administered SC
Study NCT01198002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Q4W
Description: Administered SC
Study NCT01198002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate is a background therapy.
Study NCT01198002 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate is a background therapy.
Study NCT03760445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midostaurin
Description: 25mg capsules given orally
Study NCT03760445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal cytarabine/daunorubicin
Description: 100mg/44mg or other strength as locally available given intravenously
Study NCT03760445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: posaconazole
Description: 100mg delayed release tablet or other strength as locally available given orally
Study NCT03760445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: 2mg/mL oral solution or in other strength as locally available
Study NCT02654951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual Feedback
Description: The visual feedback condition will use a monitor to display two cursors (empty circles) that will represent the participant's hands, and the circles will fill with red ink as the user starts to compensate outside a normal error band. The amount of red ink will increase proportionally to the magnitude of trunk compensation.~The goal of the participants will be to move their hands/cursors towards a target, while keeping the cursors as empty as possible.